1,200
Participants
Start Date
September 26, 2024
Primary Completion Date
July 31, 2028
Study Completion Date
July 31, 2028
Biomarker Data Collection
During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.
MK6240
Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
COMPLETED
ADRC of Albany, Albany
RECRUITING
Flourish Research - Philadelphia, Philadelphia
RECRUITING
Progressive Medical Research, Port Orange
RECRUITING
K2 Medical Research, Maitland
RECRUITING
Conquest Research, Winter Park
RECRUITING
Charter Research, Orlando
RECRUITING
Clincloud, Melbourne
RECRUITING
Visionary Investigators Network, Miami
RECRUITING
Visionary Investigators Network, Aventura
RECRUITING
Brain Matters Research, Delray Beach
RECRUITING
JEM Research Institute, Atlantis
RECRUITING
Axiom Brain Health, Tampa
RECRUITING
Neuropsychiatric Research Center of SW Florida, Fort Myers
RECRUITING
Intercoastal Medical Group, Inc., Sarasota
RECRUITING
K2 - Winter Garden, Clermont
RECRUITING
Neuro-Behavioral Clinical Research Inc., North Canton
RECRUITING
Quest Research Institute, Farmington Hills
RECRUITING
Flourish Research - Chicago, Chicago
RECRUITING
Re:Cognition Health, Houston
RECRUITING
Gadolin Research LLC, Beaumont
RECRUITING
Toronto Memory Program, Toronto
RECRUITING
NeuroClin Glasgow, Motherwell
RECRUITING
Re:Cognition Health, London
Lead Sponsor
GAP Innovations, PBC
INDUSTRY